The CMA has fined a number of pharmaceutical companies in relation to conduct and agreements between 2001 and 2004 in which GlaxoSmithKline plc agreed to make payments and other value transfers totalling over £50 million to suppliers of generic versions of GSK’s anti-depressant drug paroxetine. The CMA has decided that these payments and other value transfers were aimed at delaying the potential entry of generic competitors into the UK market for paroxetine. Click here.